Dorsey Wright & Associates Increases Stock Holdings in argenex SE $ARGX

Dorsey Wright & Associates grew its holdings in argenex SE (NASDAQ:ARGX) by 48.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,189 shares of the company’s stock after purchasing an additional 710 shares during the quarter. Dorsey Wright & Associates’ holdings in argenex were worth $1,599,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Oppenheimer & Co. Inc. boosted its position in argenex by 2.8% in the 4th quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock valued at $372,000 after buying an additional 12 shares during the period. Valeo Financial Advisors LLC increased its position in shares of argenex by 0.9% during the fourth quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock worth $1,153,000 after acquiring an additional 12 shares during the period. CI Investments Inc. increased its position in shares of argenex by 2.6% during the fourth quarter. CI Investments Inc. now owns 469 shares of the company’s stock worth $394,000 after acquiring an additional 12 shares during the period. Allworth Financial LP raised its stake in shares of argenex by 12.7% in the fourth quarter. Allworth Financial LP now owns 115 shares of the company’s stock valued at $97,000 after acquiring an additional 13 shares in the last quarter. Finally, WPG Advisers LLC raised its stake in shares of argenex by 17.8% in the first quarter. WPG Advisers LLC now owns 86 shares of the company’s stock valued at $63,000 after acquiring an additional 13 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on ARGX. Wells Fargo & Company boosted their price objective on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research report on Monday, June 1st. Royal Bank Of Canada lifted their price target on shares of argenex from $890.00 to $945.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. HC Wainwright reiterated a “buy” rating and set a $940.00 price target on shares of argenex in a report on Thursday, June 25th. Morgan Stanley increased their price objective on shares of argenex from $1,170.00 to $1,180.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Finally, Glj Research upgraded shares of argenex to a “strong-buy” rating in a report on Friday, April 3rd. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, argenex presently has an average rating of “Moderate Buy” and an average target price of $1,037.61.

argenex Trading Up 0.3%

ARGX stock opened at $860.55 on Friday. The company has a market capitalization of $53.52 billion, a P/E ratio of 38.31, a PEG ratio of 1.06 and a beta of 0.45. The business has a 50 day simple moving average of $860.97 and a 200-day simple moving average of $813.59. argenex SE has a twelve month low of $560.91 and a twelve month high of $953.58.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The firm had revenue of $1.31 billion for the quarter. Research analysts predict that argenex SE will post 26.27 EPS for the current fiscal year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.